Codexis (CDXS) Announces Retirement of Byron Dorgan from Board

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company’s Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board.

“On behalf of the entire Board of Directors, I want to express our appreciation for Byron’s valuable guidance and leadership as we collaborated to transform Codexis into a leading therapeutics manufacturing company,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “We are grateful for his longstanding dedication to the Company and wish him the very best.”

Mr. Dorgan added, “It has been a privilege to serve on the Codexis Board alongside a group of bright and passionate directors for almost 15 years. I am incredibly proud of our progress toward advancing innovative solutions like the ECO Synthesis platform, and I look forward to following Codexis through its exciting next chapter.”

With this change, Codexis will reduce the number of seats on its Board of Directors from ten to nine.

You May Also Be Interested In

• Polar Power adds two directors with defense and business experience
• Tonix Pharma CEO named interim chief medical officer
• W. R. Berkley merges two units to form Berkley Meridian